Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and maxillofacial surgeons for use in surgical procedures. It operates in five segments: demineralized bone matrix, hybrid/synthetic, traditional tissue, spinal allograft, and client services. The company processes, markets, and distributes Xenograft bone tissue products, which are used as bone graft substitutes. The company was founded in 1986 and is headquartered in Eatontown, NJ.